Positive News SentimentPositive NewsNASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis $6.53 -0.20 (-2.97%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$6.51 -0.02 (-0.35%) As of 09/11/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Maravai LifeSciences Stock (NASDAQ:MRVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Maravai LifeSciences alerts:Sign Up Key Stats Today's Range$6.49▼$6.9150-Day Range$5.68▼$9.0052-Week Range$2.55▼$9.42Volume3.26 million shsAverage Volume4.74 million shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/APrice Target$6.83Consensus RatingHold Company Overview Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry. Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows. The company’s TriLink® division supplies custom nucleic acids and enzymatic reagents for RNA and DNA synthesis, while its SeraCode™ and ExoScale™ offerings provide specialized tools for protein quantification and extracellular vesicle analysis. Maravai also offers contract development and manufacturing services to support scale-up and commercialization efforts for novel biologic candidates. Founded in 2015 and headquartered in San Diego, California, Maravai has grown through strategic acquisitions and organic innovation to serve clients in North America, Europe and Asia. The company partners with leading pharmaceutical and biotechnology organizations to advance vaccine programs, cell and gene therapies and precision diagnostics. Under the leadership of President and Chief Executive Officer Brent P. Saunders, Maravai continues to invest in research and development, expanding its global manufacturing footprint and strengthening its position in high-growth markets for advanced therapies.AI Generated. May Contain Errors. Read More Maravai LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreMRVI MarketRank™: Maravai LifeSciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 711th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingMaravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Maravai LifeSciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 3 research reports in the past 90 days.Read more about Maravai LifeSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.20) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -12.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -12.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Maravai LifeSciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.33% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 1.66, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 16.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. News and Social Media4.9 / 5News Sentiment1.84 News SentimentMaravai LifeSciences has a news sentiment score of 1.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Maravai LifeSciences this week, compared to 2 articles on an average week.Search Interest8 people have searched for MRVI on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.Percentage Held by Insiders2.49% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Maravai LifeSciences' insider trading history. Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRVI Stock News HeadlinesTEM, BNTX, MRVI, RGEN, NVAX stock rallies as Moderna-Merck cancer vaccine clears late-stage trialAugust 19, 2026 | msn.comStifel Nicolaus Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)August 15, 2026 | theglobeandmail.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.September 12 at 1:00 AM | Porter & Company (Ad)Maravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss NarrowsAugust 7, 2026 | quiverquant.comQMaravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | seekingalpha.comMaravai LifeSciences Reports Second Quarter 2026 Financial ResultsAugust 7, 2026 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 6, 2026 | seekingalpha.comMaravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026July 22, 2026 | businesswire.comSee More Headlines MRVI Stock Analysis - Frequently Asked Questions How have MRVI shares performed this year? Maravai LifeSciences' stock was trading at $3.25 at the start of the year. Since then, MRVI stock has increased by 100.9% and is now trading at $6.53. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The business earned $51.44 million during the quarter, compared to the consensus estimate of $48.67 million. Maravai LifeSciences had a negative trailing twelve-month return on equity of 15.70% and a negative net margin of 37.07%. Read the conference call transcript. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.5 billion in an initial public offering on Thursday, November 19th 2020. The company issued 60,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Maravai LifeSciences' top institutional investors include Braidwell LP (3.35%), Bank of New York Mellon Corp (0.14%), Headlands Technologies LLC (0.06%) and Public Employees Retirement System of Ohio (0.04%). Insiders that own company stock include Gtcr Investment Xi Llc, Bernd Brust, Kurt Oreshack, Carl Hull and Gregory T Lucier. View institutional ownership trends. How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Maravai LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/06/2026Today9/12/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MRVI's financial health is in the Green zone, according to TradeSmith. MRVI has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:MRVI CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees610Year Founded2014Price Target and Rating Average Price Target for Maravai LifeSciences$6.83 High Price Target$8.00 Low Price Target$6.00 Potential Upside/Downside+4.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.77 million Net Margins-37.07% Pretax Margin-65.38% Return on Equity-15.70% Return on Assets-8.17% Debt Debt-to-Equity Ratio0.49 Current Ratio4.05 Quick Ratio2.98 Sales & Book Value Annual Sales$208.78 million Price / Sales8.12 Cash Flow$0.41 per share Price / Cash Flow16.08 Book Value$1.46 per share Price / Book4.47Miscellaneous Outstanding Shares259,674,000Free Float253,208,000Market Cap$1.70 billion OptionableOptionable Beta0.60 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:MRVI) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersElon’s “nude” scandal – a big opportunity?Elon Musk's SpaceX just hit a legal snag in Minnesota over Grok's AI nudification capabilities, with the state...InvestorPlace | SponsoredWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
